MK-4482 Study in Non-Hospitalised Adults with COVID-19

---

This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29.

• https://www.clinicaltrials.gov/ct2/show/NCT04575597